San­doz signs deal for an­ti­fun­gal from Astel­las in buff-up of an­ti-in­fec­tives port­fo­lio

Gener­ics gi­ant and No­var­tis di­vi­sion San­doz signed a deal with Astel­las for world­wide rights to the an­ti­fun­gal drug mi­ca­fun­gin sodi­um, al­so known as My­camine.

San­doz and Astel­las put out word Tues­day that the deal has been signed, with a ten­ta­tive clos­ing date some­time in the first half of the year. Astel­las said in a state­ment that San­doz is pay­ing be­tween $62.5 mil­lion and $75 mil­lion up­front — de­pen­dent on when the deal ac­tu­al­ly clos­es — with po­ten­tial for mile­stone pay­ments based on sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.